In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy

被引：37

作者：

Mezzatesta M.L. ^{[1
]}

Trovato G. ^{[1
]}

Gona F. ^{[1
]}

Nicolosi V.M. ^{[1
]}

Nicolosi D. ^{[1
]}

Carattoli A. ^{[2
]}

Fadda G. ^{[3
]}

Nicoletti G. ^{[1
]}

Stefani S. ^{[1
]}

机构：

[1] Department of Microbiological and Gynaecological Sciences, University of Catania, Catania

[2] Istituto Superiore di Sanità, Roma

[3] Department of Microbiology, Policlinico Gemelli Roma, Roma

来源：

Annals of Clinical Microbiology and Antimicrobials | / 7卷 / 1期

关键词：

Ceftazidime; Imipenem; Meropenem; Colistin; Carbapenems;

D O I：

10.1186/1476-0711-7-4

中图分类号：

学科分类号：

摘要：

Background: In a recent multi-centre Italian survey (2003-2004), conducted in 45 laboratories throughout Italy with the aim of monitoring microorganisms responsible for severe infections and their antibiotic resistance, Acinetobacter baumannii was isolated from various wards of 9 hospitals as one of the most frequent pathogens. One hundred and seven clinically significant strains of A. baumannii isolates were included in this study to determine the in vitro activity of tigecycline and comparator agents. Methods: Tests for the susceptibility to antibiotics were performed by the broth microdilution method as recommended by CLSI guidelines. The following antibiotics were tested: aztreonam, piperacillin/tazobactam, ampicillin/sulbactam, ceftazidime, cefepime, imipenem, meropenem tetracycline, doxycycline, tigecycline, gentamicin, amikacin, ciprofloxacin, colistin, and trimethoprim/sulphametoxazole. The PCR assay was used to determine the presence of OXA, VIM, or IMP genes in the carbapenem resistant strains. Results: A. baumannii showed widespread resistance to ceftazidime, ciprofloxacin and aztreonam in more than 90% of the strains; resistance to imipenem and meropenem was 50 and 59% respectively, amikacin and gentamicin were both active against about 30% of the strains and colistin about 99%, with only one strain resistant. By comparison with tetracyclines, tigecycline and doxycycline showed a higher activity. In particular, tigecycline showed a MIC90 value of 2 mg/L and our strains displayed a unimodal distribution of susceptibility being indistinctly active against carbapenem-susceptible and resistant strains, these latter possessed OXA-type variant enzymes. Conclusion: In conclusion, tigecycline had a good activity against the MDR A. baumannii strains while maintaining the same MIC90 of 2 mg/L against the carbapenem-resistant strains. © 2008 Mezzatesta et al; licensee BioMed Central Ltd.

引用

共 56 条

[1]

Nicoletti G.S.G., Fadda G., Boros S., Nicolosi D., Marchese A., Spanu T., Pantosti A., Monaco M., Rezza G., Casosne A., Garaci E., Bacterial Isolates from Severe Infections and Their Antibiotic Susceptibility Patterns in Italy: A Nationwide Study in the Hospital Setting, Journal of Chemotherapy, 18, pp. 589-602, (2006)

[2]

Wilson S.J.C.K., Zieger M., Gabehart K., Goodman J., Volk H., Sood R., Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital, American Journal of Infection Control, 32, 6, pp. 342-344, (2004)

[3]

Giordano A., Varesi P., Bertini A., Villa L., Dionisi A.M., Venditti M., Carfagna P., Luzzi I., Mancini C., Carattoli A., Outbreak of Acinetobacter baumannii Producing the Carbapenem-Hydrolyzing Oxacillinase OXA-58 in Rome, Italy, Microbial Drug Resistance, 13, 1, pp. 37-43, (2007)

[4]

Bertini A., Poirel L., Bernabeu S., Fortini D., Villa L., Nordmann P., Carattoli A., Multicopy blaOXA-58 Gene as a Source of High-Level Resistance to Carbapenems in Acinetobacter baumannii, Antimicrob Agents Chemother, 51, 7, pp. 2324-2328, (2007)

[5]

Thean Yen Tan M., Karen P., Siew Y.N., Molecular Typing of Imipenem-Resistant Acinetobacter baumannii-calcoaceticus Complex in a Singapore Hospital Where Carbapenem Resistance Is Endemic, Infection Control and Hospital Epidemiology, 28, pp. 941-944, (2007)

[6]

Valenzuela J.K., Thomas L., Partridge S.R., van der Reijden T., Dijkshoorn L., Iredell J., Horizontal Gene Transfer in a Polyclonal Outbreak of Carbapenem-Resistant Acinetobacter baumannii, J Clin Microbiol, 45, 2, pp. 453-460, (2007)

[7]

Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A., The Global Challenge of Multidrug Resistant (MDR) Acinetobacter baumannii, Antimicrob Agents Chemother, (2007)

[8]

Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., Liolios L., Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 50, 9, pp. 2946-2950, (2006)

[9]

Urban C., Mariano N., Rahal J.J., Tay E., Ponio C., Koprivnjak T., Weiss J., Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI21 and Cecropin P1, Antimicrob Agents Chemother, 45, 3, pp. 994-995, (2001)

[10]

Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., Patterson D.L., Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections, The Lancet Infectious Diseases, 6, 9, pp. 589-601, (2006)

← 1 2 3 4 5 6 →